Integra LifeSciences Holdings Corporation (IART): Price and Financial Metrics


Integra LifeSciences Holdings Corporation (IART): $70.22

0.30 (+0.43%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

IART Stock Summary

  • IART has a higher market value than 75.01% of US stocks; more precisely, its current market capitalization is $5,858,649,050.
  • Price to trailing twelve month operating cash flow for IART is currently 28.74, higher than 81.22% of US stocks with positive operating cash flow.
  • In terms of twelve month growth in earnings before interest and taxes, Integra Lifesciences Holdings Corp is reporting a growth rate of 44.75%; that's higher than 78.58% of US stocks.
  • Stocks that are quantitatively similar to IART, based on their financial statements, market capitalization, and price volatility, are DCI, NUVA, PNR, BRC, and ASTE.
  • IART's SEC filings can be seen here. And to visit Integra Lifesciences Holdings Corp's official web site, go to www.integralife.com.

IART Stock Price Chart Interactive Chart >

Price chart for IART

IART Price/Volume Stats

Current price $70.22 52-week high $71.34
Prev. close $69.92 52-week low $42.12
Day low $69.62 Volume 314,000
Day high $71.07 Avg. volume 369,796
50-day MA $68.27 Dividend yield N/A
200-day MA $56.68 Market Cap 5.92B

Integra LifeSciences Holdings Corporation (IART) Company Bio


Integra LifeSciences develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neuro-surgery; U.S. Extremities; U.S. Instruments; U.S. Spine and Other; and International. The company was founded in 1989 and is based in Plainsboro, New Jersey.


IART Latest News Stream


Event/Time News Detail
Loading, please wait...

IART Latest Social Stream


Loading social stream, please wait...

View Full IART Social Stream

Latest IART News From Around the Web

Below are the latest news stories about Integra Lifesciences Holdings Corp that investors may wish to consider to help them evaluate IART as an investment opportunity.

Integra LifeSciences Shifts Toward A Better Growth/Margin Mix And Looks To Procedure Normalization

Integra LifeSciences (IART) has enjoyed a good run since the fall of 2020, rising more than 40% and handily beating the broader med-tech space. It seems as though investors have really liked the company’s decision to exit orthopedics and reallocate capital toward regenerative medicine, and that makes sense as it...

Stephen Simpson on Seeking Alpha | April 8, 2021

Integra LifeSciences to Host First Quarter 2021 Financial Results Conference Call on April 28, 2021

PRINCETON, N.J., April 08, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2021 financial results on Wednesday, April 28, 2021 prior to market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. The live call is accessible by dialing (800) 353-6461 and using the passcode 8109382. A simultaneous webcast of the call will be available via the Company’s website at www.integralife.com. A webcast replay of the call can be accessed through the Investor Relations homepage of Integra's website at www.integralife.com. A replay of the call will be available until May 8, 2021 by dialing (888) 203-1112 and using the passcode 810...

Yahoo | April 8, 2021

Is Integra LifeSciences Holdings Corporation's (NASDAQ:IART) 8.8% ROE Worse Than Average?

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Yahoo | April 3, 2021

BTIG Stick to Their Buy Rating for Integra Lifesciences Holdings Corp. By Investing.com

BTIG Stick to Their Buy Rating for Integra Lifesciences Holdings Corp.

Investing.com | March 30, 2021

Acellular Dermal Matrices Market Major Players Analysis Zimmer Biomet, Stryker Corporation, Staumann, Allergan, Inc., Conmed, Integra LifeSciences Corporation, Aziyo Biologics, Hospital Innovations, Medtronic, Inc., Synthes, Inc.

Acellular Dermal Matrices Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading players

OpenPR | March 18, 2021

Read More 'IART' Stories Here

IART Price Returns

1-mo 3.89%
3-mo 3.74%
6-mo 44.90%
1-year 48.77%
3-year 25.64%
5-year 110.02%
YTD 8.16%
2020 11.39%
2019 29.22%
2018 -5.77%
2017 11.57%
2016 26.57%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.0348 seconds.